Invesco
NGNE icon

Invesco’s Neurogene NGNE Stock Holding History

Invesco’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+6,658
New +$183K ﹤0.01% 3581
2024
Q4 		– Sell
-121,837
Closed -$5.11M – 3794
2024
Q3 		$5.11M Sell
121,837
-11,857
-9% -$460K ﹤0.01% 2209
2024
Q2 		$4.87M Buy
133,694
+11,330
+9% +$400K ﹤0.01% 2198
2024
Q1 		$6.23M Buy
+122,364
New +$4.09M ﹤0.01% 2088
2022
Q2 		– Sell
-562
Closed -$21K – 4107
2022
Q1 		$21K Buy
562
+4
+0.7% +$233 ﹤0.01% 3988
2021
Q4 		$53K Sell
558
-234
-30% -$28.5K ﹤0.01% 3975
2021
Q3 		$115K Buy
792
+88
+13% +$13.5K ﹤0.01% 3913
2021
Q2 		$130K Buy
+704
New +$156K ﹤0.01% 3858
2020
Q3 		– Sell
-1,200
Closed -$399K – 3675
2020
Q2 		$399K Buy
1,200
+107
+10% +$27.9K ﹤0.01% 3238
2020
Q1 		$249K Buy
+1,093
New +$225K ﹤0.01% 3331

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Invesco's NGNE Position: Q2 2026 in Review

Invesco opened a new position in Neurogene (NGNE) in Q2 2026: 6,658 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #3581 among its holdings. This is a return to the name: Invesco previously reported a position in NGNE as recently as Q3 2024.

Invesco first reported a position in NGNE in Q1 2020 and has held it in 10 quarters since. The position peaked at $6.23M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Invesco held 6,658 shares of Neurogene worth $209K as of Q2 2026.
  • Neurogene was a new Invesco position in Q2 2026.
  • Neurogene made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3581 holding.
  • Invesco first reported a position in Neurogene in Q1 2020 and has held it in 10 quarters since.
  • Invesco's Neurogene position peaked at $6.23M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.